Intercept Pharmaceuticals, Inc. (ICPT): Price and Financial Metrics


Intercept Pharmaceuticals, Inc. (ICPT): $15.54

1.10 (+7.62%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICPT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 455

in industry

ICPT POWR Grades


  • ICPT scores best on the Value dimension, with a Value rank ahead of 92.35% of US stocks.
  • ICPT's strongest trending metric is Value; it's been moving up over the last 169 days.
  • ICPT ranks lowest in Momentum; there it ranks in the 9th percentile.

ICPT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ICPT is -2.27 -- better than merely 3.04% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -2.96 for Intercept Pharmaceuticals Inc; that's greater than it is for only 3.16% of US stocks.
  • Over the past twelve months, ICPT has reported earnings growth of -79.55%, putting it ahead of just 21.48% of US stocks in our set.
  • Stocks that are quantitatively similar to ICPT, based on their financial statements, market capitalization, and price volatility, are KPTI, BNFT, TMDX, RDUS, and RMED.
  • ICPT's SEC filings can be seen here. And to visit Intercept Pharmaceuticals Inc's official web site, go to www.interceptpharma.com.

ICPT Valuation Summary

  • ICPT's price/sales ratio is 1.5; this is 60.53% lower than that of the median Healthcare stock.
  • ICPT's price/sales ratio has moved down 98.5 over the prior 108 months.
  • ICPT's EV/EBIT ratio has moved up 12.1 over the prior 108 months.

Below are key valuation metrics over time for ICPT.

Stock Date P/S P/B P/E EV/EBIT
ICPT 2021-08-31 1.5 -2.4 -2.9 -7.6
ICPT 2021-08-30 1.4 -2.4 -2.8 -7.5
ICPT 2021-08-27 1.4 -2.4 -2.8 -7.5
ICPT 2021-08-26 1.3 -2.2 -2.6 -7.2
ICPT 2021-08-25 1.3 -2.2 -2.6 -7.2
ICPT 2021-08-24 1.3 -2.3 -2.7 -7.3

ICPT Growth Metrics

    Its year over year net income to common stockholders growth rate is now at 36%.
  • The 5 year price growth rate now stands at -35.89%.
  • Its 5 year cash and equivalents growth rate is now at -5.66%.
Over the past 15 months, ICPT's revenue has gone up $70,981,000.

The table below shows ICPT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 354.332 -61.467 -107.293
2021-06-30 341.026 -106.584 -170.13
2021-03-31 321.699 -125.945 -222.317
2020-12-31 312.69 -170.026 -274.88
2020-09-30 300.922 -214.535 -320.891
2020-06-30 283.351 -220.813 -339.255

ICPT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ICPT has a Quality Grade of B, ranking ahead of 77.14% of graded US stocks.
  • ICPT's asset turnover comes in at 0.66 -- ranking 47th of 682 Pharmaceutical Products stocks.
  • GBT, AVDL, and SYRS are the stocks whose asset turnover ratios are most correlated with ICPT.

The table below shows ICPT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.660 0.992 -0.066
2021-06-30 0.616 0.988 -0.139
2021-03-31 0.552 0.984 -0.191
2020-12-31 0.506 0.983 -0.239
2020-09-30 0.455 0.977 -0.277
2020-06-30 0.397 0.980 -0.282

ICPT Price Target

For more insight on analysts targets of ICPT, see our ICPT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $31.63 Average Broker Recommendation 1.92 (Hold)

ICPT Stock Price Chart Interactive Chart >

Price chart for ICPT

ICPT Price/Volume Stats

Current price $15.54 52-week high $38.20
Prev. close $14.44 52-week low $11.60
Day low $13.89 Volume 811,055
Day high $15.75 Avg. volume 817,466
50-day MA $16.35 Dividend yield N/A
200-day MA $17.15 Market Cap 459.16M

Intercept Pharmaceuticals, Inc. (ICPT) Company Bio


Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic underserved liver diseases. The company was founded in 2002 and is based in New York, New York.


ICPT Latest News Stream


Event/Time News Detail
Loading, please wait...

ICPT Latest Social Stream


Loading social stream, please wait...

View Full ICPT Social Stream

Latest ICPT News From Around the Web

Below are the latest news stories about Intercept Pharmaceuticals Inc that investors may wish to consider to help them evaluate ICPT as an investment opportunity.

Top Biotech Stocks for Q1 2022

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | January 18, 2022

HealthInvest Partners AB Buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Sells ...

Stockholm, V7, based Investment company HealthInvest Partners AB (Current Portfolio) buys McKesson Corp, Cardinal Health Inc, AmerisourceBergen Corp, Bristol-Myers Squibb Co, AbbVie Inc, sells Supernus Pharmaceuticals Inc, Accuray Inc, Aldeyra Therapeutics Inc, Rigel Pharmaceuticals Inc, Evolus Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, HealthInvest Partners AB.

Yahoo | January 18, 2022

B. Riley Beefs Up Intercept Target Price On Catalyst Rich 1H 2022

B. Riley upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to Buy from Neutral with a price target of , up from $25. Analyst Mayank Mamtani sees a "catalyst rich" 1H of 2022 for the Company. The analyst notes the upcoming topline Phase 3 MAESTRONAFLD-1 study readout in F2/F3 pre-cirrhotic nonalcoholic steatohepatitis and Phase 3 REVERSE study readout in F4 compensated cirrhotic NASH. Related: Intercept Reports Narrower Q3 Loss; Raises Ocaliva Annual Sales Guidance. Last Month, Intercept Phar

Yahoo | January 11, 2022

3 Can't-Miss Biotech Events Coming Up in 2022

Here's why you'll want to keep both eyes open for upcoming announcements from Alnylam Pharmaceuticals (NASDAQ: ALNY), Intercept Pharmaceuticals (NASDAQ: ICPT), and Karuna Therapeutics (NASDAQ: KRTX). Shares of Alnylam recently slipped around 15% overnight in response to a surprising clinical-trial flop for a drug it isn't even developing. Recently, BridgeBio Pharma told investors that people with heart damage caused by transthyretin amyloidosis (ATTR) who received acoramidis failed to outperform the placebo group on the six-minute walking test.

Yahoo | January 7, 2022

Intellia (NTLA) Inks Deal With Kyverna for Autoimmune Diseases

Intellia (NTLA) inks a licensing and collaboration deal with Kyverna Therapeutics for developing an allogeneic CAR T-cell therapy for autoimmune diseases.

Yahoo | January 6, 2022

Read More 'ICPT' Stories Here

ICPT Price Returns

1-mo -9.12%
3-mo -7.83%
6-mo -10.07%
1-year -57.78%
3-year -86.17%
5-year -85.88%
YTD -4.60%
2021 -34.05%
2020 -80.07%
2019 22.95%
2018 72.53%
2017 -46.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 4.2279 seconds.